Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Elevated IgE M1 prime transcripts in nasal tissues in patients with nasal polyps and asthma.

Scheerens H, Smith A, Li O, Honigberg L, Harris JM, Holtappels G, Bachert C.

J Allergy Clin Immunol. 2019 Feb;143(2):805-807. doi: 10.1016/j.jaci.2018.10.011. Epub 2018 Oct 22. No abstract available.

PMID:
30359682
2.

Increased IgE+ B Cells in Sputum, but Not Blood, Bone Marrow, or Tonsils, after Inhaled Allergen Challenge in Subjects with Asthma.

Oliveria JP, Salter BM, MacLean J, Kotwal S, Smith A, Harris JM, Scheerens H, Sehmi R, Gauvreau GM.

Am J Respir Crit Care Med. 2017 Jul 1;196(1):107-109. doi: 10.1164/rccm.201611-2274LE. No abstract available.

PMID:
28665197
3.

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties.

Wang X, Barbosa J, Blomgren P, Bremer MC, Chen J, Crawford JJ, Deng W, Dong L, Eigenbrot C, Gallion S, Hau J, Hu H, Johnson AR, Katewa A, Kropf JE, Lee SH, Liu L, Lubach JW, Macaluso J, Maciejewski P, Mitchell SA, Ortwine DF, DiPaolo J, Reif K, Scheerens H, Schmitt A, Wong H, Xiong JM, Xu J, Zhao Z, Zhou F, Currie KS, Young WB.

ACS Med Chem Lett. 2017 May 3;8(6):608-613. doi: 10.1021/acsmedchemlett.7b00103. eCollection 2017 Jun 8.

4.

Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch.

Scheerens H, Malong A, Bassett K, Boyd Z, Gupta V, Harris J, Mesick C, Simnett S, Stevens H, Gilbert H, Risser P, Kalamegham R, Jordan J, Engel J, Chen S, Essioux L, Williams JA.

Clin Transl Sci. 2017 Mar;10(2):84-92. doi: 10.1111/cts.12455. Epub 2017 Feb 27.

5.

A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria.

Harris JM, Cabanski CR, Scheerens H, Samineni D, Bradley MS, Cochran C, Staubach P, Metz M, Sussman G, Maurer M.

J Allergy Clin Immunol. 2016 Dec;138(6):1730-1732. doi: 10.1016/j.jaci.2016.06.023. Epub 2016 Jul 19. No abstract available.

PMID:
27567329
6.

Peripheral blood gene expression predicts clinical benefit from anti-IL-13 in asthma.

Choy DF, Jia G, Abbas AR, Morshead KB, Lewin-Koh N, Dua R, Rivera P, Moonsamy P, Fontecha M, Balasubramanyam A, Santini C, Bassett E, Ray JM, Cabanski CR, Bradley MS, Maciuca R, Mosesova S, Scheerens H, Arron JR.

J Allergy Clin Immunol. 2016 Oct;138(4):1230-1233.e8. doi: 10.1016/j.jaci.2016.06.008. Epub 2016 Jun 29. No abstract available.

PMID:
27474124
7.

A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma.

Harris JM, Maciuca R, Bradley MS, Cabanski CR, Scheerens H, Lim J, Cai F, Kishnani M, Liao XC, Samineni D, Zhu R, Cochran C, Soong W, Diaz JD, Perin P, Tsukayama M, Dimov D, Agache I, Kelsen SG.

Respir Res. 2016 Mar 18;17:29. doi: 10.1186/s12931-016-0347-2.

8.

Bioanalytical challenges and improved detection of circulating levels of IL-13.

Cai F, Hornauer H, Peng K, Schofield CA, Scheerens H, Morimoto AM.

Bioanalysis. 2016 Feb;8(4):323-32. doi: 10.4155/bio.15.254. Epub 2016 Feb 5.

PMID:
26847873
9.

Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability.

Young WB, Barbosa J, Blomgren P, Bremer MC, Crawford JJ, Dambach D, Eigenbrot C, Gallion S, Johnson AR, Kropf JE, Lee SH, Liu L, Lubach JW, Macaluso J, Maciejewski P, Mitchell SA, Ortwine DF, Di Paolo J, Reif K, Scheerens H, Schmitt A, Wang X, Wong H, Xiong JM, Xu J, Yu C, Zhao Z, Currie KS.

Bioorg Med Chem Lett. 2016 Jan 15;26(2):575-579. doi: 10.1016/j.bmcl.2015.11.076. Epub 2015 Nov 24.

PMID:
26675441
10.

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.

Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H, Holweg CT, Maciuca R, Gray S, Doyle R, McClintock D, Olsson J, Matthews JG, Yen K.

Thorax. 2015 Aug;70(8):748-56. doi: 10.1136/thoraxjnl-2014-206719. Epub 2015 May 22.

11.

Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834.

Young WB, Barbosa J, Blomgren P, Bremer MC, Crawford JJ, Dambach D, Gallion S, Hymowitz SG, Kropf JE, Lee SH, Liu L, Lubach JW, Macaluso J, Maciejewski P, Maurer B, Mitchell SA, Ortwine DF, Di Paolo J, Reif K, Scheerens H, Schmitt A, Sowell CG, Wang X, Wong H, Xiong JM, Xu J, Zhao Z, Currie KS.

Bioorg Med Chem Lett. 2015 Mar 15;25(6):1333-7. doi: 10.1016/j.bmcl.2015.01.032. Epub 2015 Feb 7.

PMID:
25701252
12.

Targeting IgE production in mice and humans.

Wu LC, Scheerens H.

Curr Opin Immunol. 2014 Dec;31:8-15. doi: 10.1016/j.coi.2014.08.001. Epub 2014 Aug 25. Review.

13.

Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production.

Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, Putnam WS, Cockcroft DW, Davis BE, Leigh R, Zheng Y, Dahlén B, Wang Y, Maciuca R, Mayers I, Liao XC, Wu LC, Matthews JG, O'Byrne PM.

Sci Transl Med. 2014 Jul 2;6(243):243ra85. doi: 10.1126/scitranslmed.3008961.

14.

Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma.

Arron JR, Choy DF, Scheerens H, Matthews JG.

Ann Am Thorac Soc. 2013 Dec;10 Suppl:S206-13. doi: 10.1513/AnnalsATS.201303-047AW. Review.

PMID:
24313774
15.

OX40L blockade and allergen-induced airway responses in subjects with mild asthma.

Gauvreau GM, Boulet LP, Cockcroft DW, FitzGerald JM, Mayers I, Carlsten C, Laviolette M, Killian KJ, Davis BE, Larché M, Kipling C, Dua B, Mosesova S, Putnam W, Zheng Y, Scheerens H, McClintock D, Matthews JG, O'Byrne PM.

Clin Exp Allergy. 2014 Jan;44(1):29-37. doi: 10.1111/cea.12235.

16.

The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.

Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, Harris JM, Lee J, Jarjour NN, Matthews JG.

Clin Exp Allergy. 2014 Jan;44(1):38-46. doi: 10.1111/cea.12220.

17.

Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.

Spiess C, Bevers J 3rd, Jackman J, Chiang N, Nakamura G, Dillon M, Liu H, Molina P, Elliott JM, Shatz W, Scheer JM, Giese G, Persson J, Zhang Y, Dennis MS, Giulianotti J, Gupta P, Reilly D, Palma E, Wang J, Stefanich E, Scheerens H, Fuh G, Wu LC.

J Biol Chem. 2013 Sep 13;288(37):26583-93. doi: 10.1074/jbc.M113.480483. Epub 2013 Jul 23.

18.

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.

Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR, Zheng Y, Putnam WS, Parsey MV, Bohen SP, Matthews JG.

J Allergy Clin Immunol. 2013 Sep;132(3):567-574.e12. doi: 10.1016/j.jaci.2013.03.051. Epub 2013 May 29.

PMID:
23726041
19.

Redefining approaches to asthma: developing targeted biologic therapies.

Arron JR, Scheerens H, Matthews JG.

Adv Pharmacol. 2013;66:1-49. doi: 10.1016/B978-0-12-404717-4.00001-9. Review.

PMID:
23433454
20.

MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments.

Scheerens H, Su Z, Irving B, Townsend MJ, Zheng Y, Stefanich E, Chindalore V, Bingham CO 3rd, Davis JC Jr.

Arthritis Res Ther. 2011;13(5):R177. doi: 10.1186/ar3502. Epub 2011 Oct 26.

21.

Lebrikizumab treatment in adults with asthma.

Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG.

N Engl J Med. 2011 Sep 22;365(12):1088-98. doi: 10.1056/NEJMoa1106469. Epub 2011 Aug 3.

22.

Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study.

Zheng Y, Scheerens H, Davis JC Jr, Deng R, Fischer SK, Woods C, Fielder PJ, Stefanich EG.

Clin Pharmacol Ther. 2011 Feb;89(2):283-90. doi: 10.1038/clpt.2010.311. Epub 2010 Dec 29.

PMID:
21191378
23.

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, Young PR, Dalrymple SA, Palmer JT.

ChemMedChem. 2007 Jan;2(1):58-61. No abstract available.

PMID:
17154430
24.

Novel, potent, selective, and orally bioavailable human betaII-tryptase inhibitors.

Sperandio D, Tai VW, Lohman J, Hirschbein B, Mendonca R, Lee CS, Spencer JR, Janc J, Nguyen M, Beltman J, Sprengeler P, Scheerens H, Lin T, Liu L, Gadre A, Kellogg A, Green MJ, McGrath ME.

Bioorg Med Chem Lett. 2006 Aug 1;16(15):4085-9. Epub 2006 May 24.

PMID:
16725321
25.

IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6.

Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, Kleinschek MA, Owyang A, Mattson J, Blumenschein W, Murphy E, Sathe M, Cua DJ, Kastelein RA, Rennick D.

J Clin Invest. 2006 May;116(5):1310-6.

26.

Accelerated alveolar bone loss in mice lacking interleukin-10: late onset.

Al-Rasheed A, Scheerens H, Srivastava AK, Rennick DM, Tatakis DN.

J Periodontal Res. 2004 Jun;39(3):194-8.

PMID:
15102048
27.

Role of NADPH oxidase-derived superoxide in reduced size liver ischemia and reperfusion injury.

Harada H, Hines IN, Flores S, Gao B, McCord J, Scheerens H, Grisham MB.

Arch Biochem Biophys. 2004 Mar 1;423(1):103-8.

PMID:
14871473
28.

Accelerated alveolar bone loss in mice lacking interleukin-10.

Al-Rasheed A, Scheerens H, Rennick DM, Fletcher HM, Tatakis DN.

J Dent Res. 2003 Aug;82(8):632-5.

PMID:
12885849
29.

Regulation of postischemic liver injury following different durations of ischemia.

Hines IN, Hoffman JM, Scheerens H, Day BJ, Harada H, Pavlick KP, Bharwani S, Wolf R, Gao B, Flores S, McCord JM, Grisham MB.

Am J Physiol Gastrointest Liver Physiol. 2003 Mar;284(3):G536-45. Epub 2002 Nov 20.

30.

Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation.

Ruuls SR, Hoek RM, Ngo VN, McNeil T, Lucian LA, Janatpour MJ, Körner H, Scheerens H, Hessel EM, Cyster JG, McEvoy LM, Sedgwick JD.

Immunity. 2001 Oct;15(4):533-43.

32.

Long-term topical exposure to toluene diisocyanate in mice leads to antibody production and in vivo airway hyperresponsiveness three hours after intranasal challenge.

Scheerens H, Buckley TL, Muis TL, Garssen J, Dormans J, Nijkamp FP, Van Loveren H.

Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1074-80.

PMID:
10194148
33.

The involvement of sensory neuropeptides in toluene diisocyanate-induced tracheal hyperreactivity in the mouse airways.

Scheerens H, Buckley TL, Muis T, Van Loveren H, Nijkamp FP.

Br J Pharmacol. 1996 Dec;119(8):1665-71.

34.

Toluene diisocyanate-induced in vitro tracheal hyperreactivity in the mouse.

Scheerens H, Buckley TL, Davidse EM, Garssen J, Nijkamp FP, Van Loveren H.

Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):858-65.

PMID:
8887575
35.

Oxygen and xenobiotic reductase activities of cytochrome P450.

Goeptar AR, Scheerens H, Vermeulen NP.

Crit Rev Toxicol. 1995;25(1):25-65. Review.

PMID:
7734059
36.

Cytotoxicity of mitomycin C and adriamycin in freshly isolated rat hepatocytes: the role of cytochrome P450.

Goeptar AR, Groot EJ, Scheerens H, Commandeur JN, Vermeulen NP.

Cancer Res. 1994 May 1;54(9):2411-8.

37.

A simple and rapid in vitro test system for the screening of histamine H3 ligands.

Vollinga RC, Zuiderveld OP, Scheerens H, Bast A, Timmerman H.

Methods Find Exp Clin Pharmacol. 1992 Dec;14(10):747-51.

PMID:
1338472

Supplemental Content

Loading ...
Support Center